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Abstract
Androgen deprivation therapy, one of the standard treatments for prostate
cancer, induces apoptosis as well as autophagy in androgen-responsive PCa
cells. As modulation of autophagy is a new paradigm for enhancing the
therapeutic efficacy of various cancer therapies, we sought to determine the
functions of autophagy during androgen deprivation. In this study, we confirmed
that androgen removal or inhibition induces autophagy in two different hormone
sensitive prostate cancer cells. Androgen deprivation also caused depletion of
lipid droplets which was abrogated on inhibition of autophagy by pharmacological
means (3-methyladenine, bafilomycin A1) or using a genetic approach (Atg5
siRNA). In addition, colocalization of lipid droplets and autophagic vesicles was
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observed in LNCaP cells, which was further enhanced by blocking the
autophagic flux. These findings suggest that autophagy mediates lipid droplet
degradation and lipolysis in androgen sensitive prostate cancer cells.
Furthermore, inhibition of autophagy by chloroquine during androgen deprivation
synergistically killed LNCaP cells in a dose and time dependent manner. We
further confirmed that chloroquine caused accumulation of autophagosomes and
decreased cytosolic ATP levels. Moreover, chloroquine induced apoptosis in
androgen deprived LNCaP cells. These findings suggest that chloroquine may be
used as an adjuvant in hormone therapy to improve therapeutic efficacy.
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Chapter 1

Introduction
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1.1. Hormone ablation therapy is a standard treatment in prostate
cancer.
The prostate is a male specific exocrine gland located around the neck of
urinary bladder that encircles the urethra (1). It secretes prostatic fluid that helps in
the survival and function of sperm (1). Histologically, the prostate is made of
compound tubular structures that are lined by columnar epithelium cells. Cancer of
the prostate gland is mainly caused by neoplastic transformation of these epithelial
cells (1, 2). The incidence of prostate cancer (PCa) increases with advancing age
(3, 4). Autopsy studies showed that approximately 65% of men over 70 years of
age have some microscopic evidence of cancer in their prostate gland. However,
progression of PCa to the aggressive phenotype is not common, so active
surveillance is the mainstay of treatment in many cases (5). The American Cancer
Society estimates that that there will be 240,890 newly diagnosed cases of PCa in
2011, which makes it the most common cancer among men in the US (6). Besides
watchful waiting, the National Cancer Institute (NCI) recommends three treatment
regimens as standard therapies in early stage PCa: surgical resection, radiation
therapy and hormone ablation therapy (7). Despite advances in the treatment of
PCa, about 33,720 American men will die of it in 2011, making it the second
leading cause of cancer death in the US (6).
Androgen is a generic term for a group of natural or synthetic compounds
that stimulate male characteristics by binding the androgen receptor (AR).
Testosterone is mostly secreted by the testes and is the main androgen in humans.
Androgens are synthesized from cholesterol, so they are lipophilic which allows
2

them to easily pass through the cell membrane (8-11). In the cytosol, most
testosterone is converted into a more potent form, dihydrotesterone, by an enzyme
called 5-α reductase (9). Both testosterone and dihydrotestosterone can bind to the
androgen receptor (AR), which is a member of the steroid-thyroid-retinoid nuclear
receptor super family. Ligand binding causes AR dimerization and translocation to
the nucleus where it acts as a transcription factor. There are many genes which
are known to have upstream androgen response elements (ARE). Binding of the
androgen-AR complex along with other co-factors leads to transcriptional
regulation of hundreds of genes that affect survival, and proliferation of prostate
epithelial cells (10-14).
During PCa progression (Figure 1.1), hormonal effects of androgen
stimulation are intact during the initial phase of PCa, also called the androgendependent phase (15). Charles Brenton Huggins received a Nobel Prize in
medicine in 1966 for his discoveries of hormonal treatment of prostate cancer (16).
He showed that orchiectomy (surgical removal of the testes), induces regression of
PCa. This discovery set the foundation for hormone ablation therapy in PCa
treatment. Different drugs are available nowadays that interfere at different steps of
androgen synthesis and/or function. Hormone withdrawal or inhibition of AR
induces apoptosis in both normal prostate epithelial cells and androgen-dependent
prostate cancer cells. However, some of these cancer cells can survive and
eventually develop into an androgen-independent phenotype (17, 18).
Development of resistance to the hormone is the end stage for the prognosis of
PCa for which there are very limited treatment options. During progression
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alterations in a variety of cellular pathways take place that t help PCa cells survive
and proliferate (19, 20). Understanding the cellular mechanisms that permit
survival during androgen deprivation may help us to identify novel targets that can
be used as an adjuvant in hormone ablation therapy for PCa.

Figure 1.1. Progression of PCa and available treatment options. Most PCa
cells originate from the columnar epithelial lining of the peripheral zone of the
prostate gland. Cancer cells are initially confined within the basement membrane.
During tumor progression, PCa cells acquire the capacity to invade and
metastasize to other organs. Initially, they are androgen sensitive and respond well
to hormone inhibition or withdrawal. However, some of the cancer cells acquire
castration resistance to survive and proliferate in the absence of androgen.
Treatment options are limited for castration resistant prostate cancer.
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1.2. Androgen deprivation induces autophagy in LNCaP cells.
Historically, autophagy is defined as a highly conserved catabolic process
in eukaryotes in which aberrant organelles along with a portion of cytoplasmic
constituents are sequestered into double or multilayered membrane vesicles,
known as autophagic vesicles (AVs), and then targeted to the lysosomes for
degradation (22-24). Autophagy is inducible by nutrient starvation and is pivotal for
the maintenance of cellular energy homeostasis (22). In addition, autophagy
normally functions in removing damaged organelles, especially mitochondria, and
thus reduces the possibility of reactive oxygen species (ROS) leakage from
damaged mitochondria into the cytosol (25, 26).
Autophagy has been extensively studied in the last decade. Its function in
the pathogenesis of several diseases including its paradoxical function in cancer
treatment is a hot topic in research (27-32). Many studies suggest that autophagy
plays a prosurvival role in tumor biology. BECLIN1 is a tumor suppressor gene that
inhibits tumorigenesis in prostate cancer, breast cancer and ovarian cancer (33).
Allelic loss of BECLIN1 occurs at high frequency in prostate and breast cancer.
Moreover, BECLIN1+/- mice are tumor prone, suggesting that autophagy is a
tumor suppression mechanism. In addition, certain oncogenes, for example, AKT
and c-myc, are found to inhibit autophagy (33-35). Likewise, tumor suppressor
genes, for example, PTEN and p53, are able to induce autophagy by inhibiting
mTOR activity (35-38). Some studies have shown that autophagy has a pro-
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survival effect in cancer especially in cells at the inner core of the tumor mass
which are deprived of nutrients from the circulation (39).
Interestingly, it has been observed that autophagy is induced during different
cancer therapies, and may mediate cancer cell death. Many cancer treatments like
tamoxifen, rapamycin, and arsenic compounds are found to trigger autophagy (4043). In PCa, gamma radiation induces autophagy and confers anti-tumor activity by
mediating autophagic cell death (44). We previously showed that Apolipoprotein
L1, a novel BH3-only protein, induces autophagic cell death in several cancer cells
(45, 46). However, the presence of autophagosomes in cancer cells during
treatment is not always indicative of a pro-death mechanism. Treatment of two
human PCa cell lines, PC-3 and LNCaP, with another promising anti-cancer drug,
Sulforaphane, induces autophagy that protects cancer cells from death (47). The
effects of autophagy on cell survival and death have intrigued scientists and
provoked numerous investigations of whether modulation of autophagy can be a
treatment option in cancer.
As stated earlier, hormone ablation therapy is a standard treatment in PCa.
Androgens are a steroid hormones that stimulate growth of prostate epithelial cells.
Growth factors are key regulators of autophagy in many cell types and do so by
modulating the activity of the mTOR signaling pathway (23). It has been reported
that in LNCaP cells, androgens stimulate the activity of mTOR, a known inhibitor of
autophagy (48). In another study, incubation of LNCaP cells in serum free medium
causes loss of phosphorylation of p70 ribosomal S6 kinase, a downstream effector
of mTOR. This effect can be reversed by the addition of dihydrotestosterone (DHT)
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(49). The study further showed that serum deprivation induces autophagy which is
markedly suppressed by DHT. These results suggest a negative regulation of
autophagy by androgens in LNCaP cells, and that autophagy is induced during
androgen-deprivation therapy. However, androgens did not affect autophagy in the
androgen-resistant prostate cancer PC3 cell line (49). These results are consistent
with an in vivo report, where increased numbers of autophagosomes were
observed in the prostate epithelial cells of castrated mice (50).
Inhibition of autophagy in LNCaP cells under serum-free conditions causes
increased cell death, suggesting that autophagy protects LNCaP cells (49).
However, the molecular mechanism underlying the prosurvival effect of autophagy
varies in different cells. Elucidating the molecular events that are regulated by
autophagy during androgen deprivation is critical to understanding if regulators of
autophagy can be used as therapeutic targets in prostate cancer treatment.

1.3. Autophagy plays an important role in cellular bioenergetic
balance.
One of the best defined prosurvival functions of autophagy is its impact on
cellular bioenergetic balance. Autophagy has been shown to contribute significantly
to the degradation of protein aggregates, aberrant organelles, lipid droplets and
glycogens (Figure 1.2) (51-54). Thus released amino acids, fatty acids and glucose
can serve as precursors for both biosynthesis as well as bioenergetic fuels. This
function of autophagy is more pronounced during starvation when there is scarcity
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of nutrients, but evidence suggests that cells can induce autophagy to maintain
energy homeostasis under other conditions as well (55-57).
Autophagy is an evolutionarily conserved process of “self-eating” . The
function of autophagy is to target the cargo to the lysosome, which is the cellular
digestive organelle. There are three different types of autophagy; macroautophagy,
microautophagy, and chaperone mediated autophagy (CMA) (58). Cargo transfer
by the double or multilayered membrane vesicles into the lysosome is called
macroautophagy, but it is generally denoted by the term “autophagy” (58).
Microautophagy takes place in the lysosomal membrane where the membranes
are pinched from inside (59). Chaperone-mediated autophagy plays a role in the
translocation of cytosolic proteins to the inside of lysosomes (60).
Autophagy can sequester the cargo by both random and selective
mechanisms (61-63). Selective autophagic sequestration is named based on the
target organelle, for example mitophagy, lipophagy, ribophagy, aggregophagy etc.
Different cargos are recognized and targeted to the limiting membranes of the
newly formed autophagosomes by adaptor proteins including p62 and NBR1. (62,
63). The initiation of autophagic processes in each of these types of autophagy is a
complex process and is regulated by multiple mechanisms. Here, autophagic
regulation in response to cellular energy status is described.
Mammalian target of rapamycin complex 1 (mTORC1) is a critical nutrient
sensor that regulates autophagy in response to cellular energy status. mTORC1
negatively regulates autophagy (64). The protein kinase activity of mTORC1
phosphorylates ULK1 which then forms a complex with Atg13 and FIP200 (65, 66).
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An active Atg1-Atg13 complex is required for the initial shuttling of Atg9 to the site
of autophagosome formation (66). mTORC1 also negatively regulates autophagy
by activating another negative regulator of autophagy, called death associated
protein 1 (DAP1) (67). Lower cellular energy is also sensed by another energy
sensor, AMP-activated protein kinase (AMPK) (68-71). AMPK positively regulates
autophagy by multiple mechanisms. It can inhibit mTORC1 by phosphorylating
TSC2 complex and Raptor. It can also affect the induction of autophagy by
regulating the activity of p53 (70-72).
Autophagy is a major catabolic process for long-lived proteins (73). In fact,
cellular levels of long-lived proteins can be used as a measure of the autophagic
flux. Protein aggregates are also sequestered by the autophagosomes and
targeted to lysosomes (74). Lysosomal proteases break down the proteins into
amino acids, which are then recycled back to the cytosol. Amino acids are used in
cells for both protein synthesis and fuel supply depending on the cellular metabolic
status. Interestingly, deprivation of essential amino acids also induces autophagy
(75).
Another energy depot in cells is glycogen. Usually breakdown of glycogen
into glucose occurs in the cytosol; however acid glycosidases present in the
lysosomes can contribute to glucose generation during acute nutrient starvation
through an autophagolysosomal process (76, 77).
Although the contribution of autophagy to protein and glycogen metabolism
has been long known, its effect in lipid metabolism was only recently identified.
Lipids are stored in the cytosol in single layered organelles called lipid droplets
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(LDs) (78). These mainly consist of neutral lipids, triglycerides and cholesterol
esters. Though the precise mechanism of lipid droplet formation is still elusive, they
are presumed to be formed in the ER membrane where the diacylglycerol
acyltransferases (DGAT) and acyl CoA: cholesterol acyltransferases (ACAT)
enzymes are localized. These enzymes catalyze the final step in the synthesis of
triacylglycerols and cholesterol esters, respectively (79).
There are many proteins embedded in the membrane of the lipid droplets,
most of which are temporally targeted to the surface (80, 81). Members of the PATdomain (perilipin, ADRP and TIP47-related proteins) family of proteins are well
studied in the function of lipid droplets (78, 81). Among them, perilipin plays an
important role in maintaining their homeostasis. Glucagon, catecholamine, and
TNF can promote lipid droplet breakdown (lipolysis) by activation of cyclic-AMPdependent protein kinase (PKA), which then phosphorylates perilipin. PKA also
phosphorylates hormone sensitive lipase (HSL) which is then translocated from the
cytosol to the membrane of lipid droplets (79, 82). HSL interacts with perilipin and
mediates lipolysis. Phosphorylation of perilipin also recruits another protein, CGI58, which then promotes the translocation of adipose tissue triglyceride lipase
(ATGL). Both HSL and ATGL are cytosolic lipases which break down triglycerides
into fatty acids (Figure 1.3). The released fatty acids are further oxidized in the
peroxisomes and the mitochondria to generate acetyl-CoA.
An alternative pathway of lipolysis was recently identified and is a significant
breakthrough in our understanding of lipid metabolism. Autophagy was observed to
mobilize lipid droplets to lysosomes in rat hepatocytes (83). Inhibition of autophagy
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by chemical or genetic means leads to reduced β-oxidation and marked
accumulation of lipid droplets. Moreover, autophagosomes and lipid droplets were
associated as evidenced by colocalization assay and increased LC3-II in the lipid
droplet fraction isolated from rat hepatocytes. Lipid droplets were also observed in
the lumen of autophagosomes by electron microscopy. This cellular process of lipid
droplet sequestration by autophagosomes is named lipophagy (84-90).
Lysosomes are important cellular organelles for intracellular digestion. They
contain different hydrolases like lipases, proteases, glycosidases, and
nucleotidases, which help them to degrade macromolecules (85-87). Lipids can
also be targeted to lysosomes through the endocytic pathway (91, 92).
Lipophagy could be a critical biochemical pathway in cells that rely on lipid
metabolism such as PCa cells.. They are rich in lipid droplets and depend on βoxidation for their bioenergetic supply (93, 94). Fatty acid synthase (FAS) is highly
expressed in LNCaP cells and its inhibition or knockdown significantly inhibits cell
survival, suggesting that lipid metabolism is critical for PCa progression (95, 96).

Figure 1.2. Effects of autophagy in cellular metabolism. Autophagy can
sequester protein aggregates, aberrant organelles, glycogens and lipid droplets as
its cargo and deliver to lysosomes for degradation. The lysosomal acidic
hydrolases are known to breakdown these biomolecules into amino acids, fatty
acids and glucose, which can further be recycled for biosynthesis or utilized as fuel
precursors for generation of energy depending on the cellular nutritional and
metabolic status.
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Figure 1.3. Lipid droplets and regulation of lipolysis. Lipid droplets are
intracellular vesicles containing triglycerides and cholesteryl esters that are
surrounded by a monolayer of lipids. Different PAT-family member proteins
(Perilipin, ADRP, TIP-47), anchor protein Rab 18, diacylglycerol transferase
(DGAT2) and others are known to reside in the membrane. Targeting of many lipid
droplets proteins is temporally regulated. Upstream signals activate PKA which
then phosphorylates both perilipin and HSL. Perilipin also recruits another lipase,
ATGL, with the help of CGI-58. Translocation of lipases to the membrane results in
the breakdown of triglycerides into fatty acids.

1.4. Prostate cancer cells have a unique intermediary metabolism
that is regulated by androgens.
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Cancer cells frequently change their metabolome compared with
untransformed cells by reprogramming various metabolic pathways (97, 98).
Uncontrolled proliferation of cancer cells requires a higher supply of energy as well
as increased amounts of synthetic precursors. Most likely, increased genomic
instability in cancer cells, in both nuclear and mitochondrial DNA provides selective
pressures to shift to a new metabolome that favors cancer cell survival and
proliferation. Over the last century, we have witnessed an enormous surge in our
knowledge regarding the biochemical pathways that cells use to maintain energy
homeostasis, to sense their bioenergetic status, and to regulate catabolic and
anabolic pathways. The observation that cancer cells use an atypical biochemical
pathway for their energy supply was made around 70 years ago by Otto H Warburg
for which he was awarded the Nobel Prize (99, 100). Typically, cells breakdown
single molecule of glucose into two molecules of pyruvate which is then shuttled
into mitochondria for use as a substrate in the TCA cycle. During strenuous
exercise, muscle cells cannot get oxygen to sustain their TCA cycle at a sufficient
rate and use alternate pathways to convert pyruvate to lactate (101). In
contradiction to the typical glycolytic pathway, Warburg observed that solid tumor
cells use increased lactic fermentation even in the presence of oxygen. This type of
atypical glycolysis is called aerobic glycolysis, and is commonly referred to as the
“Warburg effect” in his honor (102).
However, the Warburg effect is not an essential event in all types of cancer.
Prostate cancer cells have unique intermediary metabolism that is tightly regulated
by androgens and their downstream transcription factors (103-105). More
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interestingly, normal prostate epithelial cells themselves have a distinct metabolic
pathway which we need to understand before we look at alterations in malignant
cells.
The prostate gland has three anatomic regions called the transition, central
and the peripheral zones. About 80% of prostate cancer originates in the peripheral
zone, so the metabolism described pertains to the epithelial cells of this
region(106). The epithelial cells of the peripheral zone are specialized citrateproducing secretory cells. Citrate is synthesized in mitochondria in the first step of
the TCA cycle by condensation of acetyl-CoA with oxaloacetate by the enzyme
citrate synthase. Further isomerization of citrate to isocitrate is severely limited in
these cells by inactive m-aconitase which causes accumulation of high amounts of
citrate in these cells and is subsequently secreted in the prostatic fluid. Normal
prostate tissue from peripheral zones has around 13000 nmol/g of citrate (107,
108).
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Figure 1.4. Metabolism in normal prostate cells. Prostate epithelial cells have
unique metabolism. High intramitochondrial zinc inhibits the enzyme aconitase and
shuts down the TCA cycle. The accumulated citrate diffuses to the cytosol. The
lipogenic enzymes are also less active, so the majority of citrate is secreted out in
the prostatic fluid. This is believed to provide nourishment and other functions for
the sperm.

These citrate-producing normal epithelial cells transform metabolically to a
citrate-oxidizing phenotype in prostate cancer cells (107, 109). The high level of
16

intramitochondrial zinc is responsible for inhibition of m-aconitase in normal cells.
The level of zinc is found to decrease in malignant cells and plays an important role
in allowing the further oxidation of citrate in the TCA cycle. However, more
importantly, androgens play a key role in regulating the consumption of acetyl-CoA
for synthesis of lipids (110-112). The citrate level from prostate cancer tissues falls
to 500 nmol/g (107).
Androgens act by binding to the androgen receptors and regulating the
expression of hundreds of genes affecting cellular metabolism, survival, and
growth. Androgens affect the transcription of many genes that encode lipogenic
enzymes (113). Transcriptional regulation of these genes is a complex process that
is regulated by the SREBP (sterol-regulatory element binding protein) family of
transcription factors (114). Evidence suggests that androgens affect the activation
of SREBPs by a coordinated multistep mechanism (115-117). The most notable
enzymes affected by the androgens are fatty acid synthase and ATP-citrate lyase,
which are involved in the synthesis of fatty acids. Other lipogenic enzymes that are
affected by androgens are acetyl-CoA carboxylase, and acetyl-CoA binding protein
(116), and expression of fatty acid synthase is correlated with the tumorigenicity in
prostate cancer (95).
Cells use excess fatty acids in the cytosol to produce triacylglycerols which
are stored in lipid droplets. Lipid droplets are intracellular depots of neutral lipids
(both triacylglycerols and cholesterols) which are enwrapped in a monolayer of
phospholipids associated with various proteins (81, 82). Hormone regulated
cytosolic lipases are known to break down triacylglycerols in lipid droplets into fatty
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acids (117). These fatty acids can act as substrates for synthesis of lipids in the
endoplasmic reticulum or as energy precursors for β-oxidation in the mitochondria.
In prostate cancer cells, androgens also regulate many enzymes involved in fatty
acid oxidation, making it the dominant metabolic pathway (94, 109, 118).
This evidence suggests that androgens are key regulators of metabolism in
prostate cancer and account for the metabolic transformation from the citratesecreting phenotype to the citrate-oxidizing phenotype. As metabolic
transformation in cancer was recently added to the list of hallmarks of cancer
(119), it further emphasizes the importance of studying the metabolic alterations
that happen in the PCa cell during androgen deprivation.
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Figure 1.5. Metabolism in prostate cancer. In comparison to normal prostate
epithelial cells, intracellular citrate in PCa cells is markedly reduced. Low amounts
of zinc in cancer cells allow m-aconitase to isomerize citrate to isocitrate. This
causes increase in flow of the intermediates in the TCA cycle. More importantly,
androgens stimulate many enzymes involved in lipogenesis (red colors) and βoxidation of fatty acids. This metabolic transformation of PCa cells helps them to
fulfill their increased bioenergetic demand.

1.5. Autophagy can be modulated at various stages.
Autophagy is generally divided into three phases: initiation, elongation, and
maturation (22). The phosphatidylinositol phosphates (PIPs) play an important role
in providing docking sites for various membrane trafficking events (22-24). During
the initiation phase of autophagosome formation, class III PI3K vacuolar protein
sorting 34 (Vps34) forms a complex with BECLIN1 and p150; and phosphorylates
the PI3P to provide docking sites for recruitment of other molecules (120). Bcl-2,
JNK1, AMBRA1, Atg14 and Bif-1 are known to differentially regulate the activity of
this complex (121-125). Vps34 can be inhibited by 3-methyladenine or BECLIN1
knockdown (74). Furthermore, a ubiquitin-like reaction mediated by Atg7 (E1-like
enzyme) and Atg10 (E2-like enzyme) conjugates Atg5 and Atg12; which later
interacts with Atg16L proteins to make a complex of Atg12-Atg5-Atg16L (23). This
complex is important for the formation of autophagosomes. Knockdown of Atg 5
and Atg 7 genes revealed that they are essential in the formation of
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autophagosomes. Therefore these genes are commonly targeted for inhibiting
autophagy in experimental studies.
Another ubiquitin-like conjugation process involving lipidation of LC3 is
important for elongation of the autophagic membrane (126-127). LC3 is first
cleaved by Atg4 to expose its C-terminal glycine. Then Atg7 (E1-like enzyme) and
Atg3 (E2-like enzyme) mediate conjugation of the C-terminal glycine of LC3 with
the amino head of phosphotidylethanolamine (PE). LC3 is a cytosolic protein, but
after lipidation it translocates to the newly forming autophagic membranes. This
translocation process is widely used to monitor autophagic activity in cell systems.
Importantly, the lipidated form runs a little faster in polyacrylamide gel
electrophoresis and forms a distinct band in immunoblots (128).
During the process of autophagosome formation, cargo can be targeted
selectively into the lumen of autophagosomes by various adaptor proteins like p62,
Nix, NBR1 and ALFY (62, 63, 129, 130). However, the mechanism of selectivity in
targeting the lipid droplets is still unknown. In some experiments, autophagosomes
were observed to form from the membranes of lipid droplets, supporting the new
concept that autophagosomes may start forming at the target site (83).
Once the autophagosomes are fully formed, they fuse with late endosomes
or lysosomes, and the cargo is delivered to the lumen of lysosomes. Different
acidic hydrolases are known that degrade those biomolecules to their basic
building blocks (85-87). Acidity is important in the activity of these hydrolases, thus
drugs that increase the pH of lysosomes interfere in the degradation of
autophagosomes. Bafilomycin A1 is a H+K+ ATPase inhibitor, which diminishes the
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acidification of lysosomes (131). Another drug, chloroquine, sequesters protons
and increases the pH (132). Alteration in pH also affects the fusion process of
autophagosomes with lysosomes, causing accumulation of autophagosomes.
Recently it was found the BECLIN1/Vps 34 complex also plays a role in the
maturation of autophagosomes. Interestingly, UVRAG positively regulates the
activity of BECLIN1 in the maturation process while Rubicon does the opposite
(133, 134).

Figure 1.6. Autophagy can be regulated at different stages. Autophagosome
formation can be divided into 3 different phases: initiation, membrane elongation
and maturation. Beclin1 siRNA, Atg5 siRNA, Atg7 siRNA and 3-MA are widely
used to inhibit the autophagy initiation phase, so there will be no autophagosome
formation at all. Bafilomycin A1 and chloroquine are used to inhibit the maturation
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process of autophagosomes. They cause accumulation of autophagosomes and
autophagolysosomes.

1.6. Chloroquine is a potent adjunct in various cancer therapies.
Chloroquine (N’-(7-chloroquinolin-4-yl0-N,N-diethyl-pentane-1,4-diamine) is
a drug that has been used widely since the second world war for chemotherapy
against malaria (135). It is also used as mild immunosuppressant in the treatment
of rheumatoid arthritis and Lupus (136, 137). Recently, it has been observed that
chloroquine can be used as an adjunct in various cancer therapies.
Chloroquine is a weak base (pka1=8.1, pka2=10.2) which can exist in both
protonated and unprotonated forms. Its charge determines its pharmacodynamics
and biodistribution (135). Because the unprotonated form is freely diffusible
through the plasma membrane, chloroquine has a large volume of distribution. But
once it gets into the lysosome, it gets protonated and cannot diffuse through the
membrane. This trapping of chloroquine in the lysosomal compartment causes an
increase in pH and subsequent inactivation of acidic hydrolases. This effect of
chloroquine also inhibits the maturation of autophagosomes (138).
Inhibition of the maturation process of autophagy by chloroquine is
potentially important in cancer therapies where cells induce autophagy as a
protective mechanism. Interestingly, chloroquine may also affect cancer growth
in other ways; chloroquine can act as a weak DNA intercalating agent and halts
the DNA repair process (139). This function has been found to be useful in
potentiating the killing effect of radiation in some cancer cells (135). However,
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effects of chloroquine on arresting the maturation of autophagosomes have been
observed in many cell types. In human retina ARPE-19 cells, chloroquine
caused arrest of autophagy, lysosomal dilatation and subsequent cell death
(140). Similarly in fibroblasts, leukocytes and myocytes, chloroquine caused
accumulation of autophagic vacuoles and affected cellular metabolism (141144).Recently, it was shown to enhance the therapeutic efficacy of topotecan in
lung cancer cells by inhibiting autophagy (145).
Similarly, in HT-29 colon cancer cells, chloroquine was observed to
potentiate the anti-cancer effects of 5-Fluorouracil (5-FU) (146). However, on
investigation it was found that 5-FU induces autophagy and use of chloroquine
inhibits autophagosomal degradation. In another study, chloroquine induced
dose dependent cell death in 5 different glioblastoma cell lines that were of
different p53 status (147). It suggests that chloroquine also affects the cell death
beyond its effects on DNA repair processes. Furthermore, they found that
chloroquine induces accumulation of autophagic vacuoles in all cell lines and
affects the levels and subcellular distribution of Cathepsin D. These findings
suggest that altered lysosomal function may play a role in chloroquine induced
cell death. Inhibition of autophagy by chloroquine also sensitizes PCa cells to Src
family kinase inhibitors like saracatinib and PP2 (148). Src kinase inhibitors
induce autophagy in both LNCaP and PC-3 cells. Autophagy blockade by
chloroquine or 3-MA or Atg7 siRNA during Src kinase inhibitor treatment caused
more cell death in vivo and in vitro.
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1.7 Hypothesis
Androgen deprivation induces autophagy in hormone sensitive prostate
adenocarcinoma LNCaP cells. Elucidating the molecular effects of autophagy
during androgen deprivation is important in understanding whether modulators of
autophagy can be used as therapeutic agents in prostate cancer treatment.
Recently, autophagy has been shown to regulate lipolysis in rat hepatocytes.
Prostate cancer cells are also rich in lipid droplets and rely predominantly on lipid
oxidation. This novel function of autophagy may be crucial in survival of prostate
cancer cells during androgen deprivation. Therefore, I hypothesize that
autophagy mediates lipophagy in androgen-dependent prostate cancer cells
and thus helps them to survive in the absence of androgen.
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Autophagy regulates lipolysis and cell survival
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2.1. Abstract
Background: Androgen deprivation therapy, one of the standard treatments for
prostate cancer (PCa) induces apoptosis, as well as autophagy in androgenresponsive PCa cells. As autophagy can promote either cell survival or death, it
is important to understand its role in PCa treatment. The objective of our study
was to elucidate the function of autophagy in lipid droplet homeostasis and
survival in androgen-sensitive PCa cells.

Methods: To produce androgen deprivation, charcoal filtered serum or the
androgen inhibitor casodex were used in LNCaP and LAPC4 cells. Autophagy
was monitored by immunofluorescence/confocal microscopy and immunoblot
analysis. Levels of intracellular lipid droplets and triacyglycerols after the
inhibition of autophagy by 3-methyladenine, bafilomycin A1 or si-ATG5 were
quantified by three independent methods, Oil Red O staining, triacyglycerols
lipase assay, and nuclear magnetic resonance.

Results: Androgen deprivation induced autophagy and the depletion of lipid
droplets in both of the androgen-sensitive PCa cell lines examined, whereas the
blockage of autophagy by pharmacological or genetic means inhibited lipid
droplet degradation and therefore lipolysis and cell growth. In addition, under
androgen deprivation, increased colocalization of lipid droplets and autophagic
vesicles was observed in LNCaP cells, which can be further enhanced by
blocking the autophagic flux.
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Conclusion: Autophagy mediates lipid droplet degradation and lipolysis in
androgen-sensitive PCa cells during androgen deprivation which aids the survival
of PCa cells during hormone ablation therapy.

Keywords: Prostate cancer, Autophagy, Androgen deprivation, Lipid droplets,
Lipolysis, NMR
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2.2 Introduction
The presence of normal concentrations of androgens is a critical
requirement for the survival, proliferation and progression of prostate epithelial
cancer (PCa) (1). These steroids act by binding to the androgen receptor (AR)
and regulating the expression of hundreds of genes affecting cellular metabolism,
survival and growth. One effect of androgen/androgen receptor axis is the
stimulation of fatty acid synthase in the human prostate adenocarcinoma cell line
LNCaP, resulting in an accumulation of lipid droplets within the cytoplasm (96,
149, 150). The activities of several other enzymes, including Acetyl-CoA
carboxylase and ATP-citrate lyase, that are involved in the synthesis of fatty
acids, are also increased in PCa (14, 93, 151, 152). Interestingly, fatty acid
oxidation is also enhanced in PCa (94, 103, 107, 108). Tumors need unusual
amounts of energy and biosynthetic precursors to survive and grow (97) and the
alterations in metabolic pathways observed in PCa cells helps them to satisfy this
increased bioenergetic demand.
It is well known that androgen ablation induces apoptosis and regression
of prostate tumors, and that this forms the basis of hormone ablation therapy in
PCa ( 153, 154). However, some of the cancer cells can “escape” from the
treatment, survive and develop androgen independence by several mechanisms
(19, 20). In order to understand the progression of PCa it is important to
investigate the cell survival mechanisms activated during hormone ablation
therapy.
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Autophagy is a cellular mechanism that is inducible during starvation and
stress (22, 45). The process involves the formation of double or multilayered
vesicles, known as autophagosomes, that enwrap cytosolic components and
target them to lysosomes for hydrolysis. This mechanism of intracellular bulk
digestion and degradation provides precursors for metabolism in cells (22). A
protein known as light chain 3 isoform I (LC3I) of the microtubule associated
protein complex 1 is essential for the autophagy pathway: activation and
translocation of lipidated LC3 isoform II (LC3II) to autophagosomes is correlated
with the induction of autophagy and is one of the markers of autophagy. Like
other metabolic pathways, autophagy can be regulated by various inducers and
inhibitors. For example, serum or amino acid deprivation induces autophagy,
whereas 3-Methyladenine (3-MA), an inhibitor of class III PI3 kinase, blocks the
generation of phosphatidylinositol 3-phosphate (PI3P), an essential docking
molecule for the formation of phagophores and the early stage of autophagy. In
addition, antibiotics, such as bafilomycin A1 (Baf A1) and concanamycin A, are
used to investigate the autophagic flux because they inhibit H+-V-ATPase
activities and acidification of the lysosome, and therefore the final fusion event
between the lysosome and autophagic vesicles (155, 156). In PCa research, it
has been shown that when androgen-sensitive LNCaP cells were cultured in
serum free medium, autophagy was induced which was diminished by adding
dihydrotestosterone, suggesting a negative regulation of autophagy by androgen
(49). In addition, two independent studies have demonstrated that inhibition of
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autophagy in LNCaP cells under androgen deprivation causes increased cell
death, suggesting that autophagy protects PCa cells (49, 157).
Lipid droplets (LDs) are intracellular depots of neutral lipids (both
triacylglycerols and cholesterols) which are enveloped by a monolayer of
phospholipids and associated proteins (158). LDs can be metabolized by at least
two different pathways. First, hormone-regulated cytosolic lipases break down
the triacylglycerols into fatty acids which are then utilized for β-oxidation (81,
158). Second, lipolysis can be mediated by autophagy. A recent study showed
that autophagosomes sequester lipid droplets and target them to the lysosome
for lipolysis in rat hepatocytes (83). Autophagic vesicles (AVs; autophagosomes,
amphisomes and autolysosomes), and LDs have been found to be colocalized in
starved rat hepatocytes. This alternate pathway of lipolysis by autophagy is
significant for intracellular lipid metabolism (85, 88), and could be critical for PCa
cell survival under androgen deprivation conditions.
As lipolysis appears to provide critical support for the progression of
prostate cancer, we propose that autophagy regulates lipolysis in androgensensitive PCa cells during androgen ablation. In this study, we sought to
determine how androgen-sensitive PCa cells could ramp up an alternate pathway
of lipid catabolism during androgen deprivation. We find that in two different
androgen-sensitive PCa cell lines, LNCaP and LAPC4, AVs sequester and target
lipid droplets to lysosomes during androgen ablation.
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2.3. Materials and Methods
Chemical and reagents. We purchased charcoal-filtered fetal bovine serum
(CFM) from Hyclone (Thermo Fisher, MA, USA), RPMI 1640, low glucose DMEM
medium and regular FBS from Invitrogen (Eugene, OR, USA), Methyltrienolone
(R1881) from PerkinElmer (Waltham, MA, USA), 3-Methyladenine (3-MA), Oil
Red O, deuterium oxide (D2O), deuterochloroform (CDCl3), tetramethylsilane
(TMS), d6-2,2-Dimethyl-2-silapentane-5-sulfonic acid (DSS) and casodex (CDX)
from Sigma-Aldrich (St Luis, MO, USA), HCSLipidTOX Red, Lipofectamine, and
G418 from Invitrogen, and bafilomycin A1 (Baf A1) from A.G. Scientific, Inc (San
Diego, CA, USA).
Cell culture and transfection with pEGFP-LC3. Human prostate cancer cells
LNCaP (American Type Culture Collection, Manassas, VA) were grown in RPMI
1640 medium with 10% (v/v) fetal bovine serum (FBS) at 37oC and 5% CO2 as
previously described (159). LAPC4 cells, an androgen-sensitive, AR- wildtype
PCa cell line, a gift from Dr. Todd Thompson (University of New Mexico Health
Science Center) (160, 161), were grown in low glucose DMEM medium with 5 %
(v/v) FBS. Media containing regular FBS were designated as CM. To treat cells,
both cell lines were grown in medium with charcoal-filtered FBS, designated as
CFM, in the presence or absence of androgen analogue (R1881), antiandrogen
(casodex/CDX), or autophagy inhibitors (3-MA or Baf A1), as indicated. The
pEGFP-LC3 plasmid containing a fusion gene of the two full-length cDNA
sequences encoding the enhanced green fluorescent protein (EGFP) and
microtubule-associated protein 1 light chain 3 (LC3), was a gift from Dr. Noburu
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Mizushima (National Institute for Basic Biology, Okazaki, Japan). pEGFP-LC3
was linearized with StuI and transfected into LNCaP cells using Lipofectamine.
Stably-transfected clones were selected by continuous culture in G418 (400

Cell viability assay. LNCaP cells were seeded in 96-well plates (10,000
cells/well) and cultured in CM, CFM or CFM+3-MA for 4 days. The cell viability
was then examined by 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay following the manufacturer’s protocol (Vybrant MTT assay,
Invitrogen).
Si RNA knowdown of ATG5. Si-Control and si-ATG5 duplexes (27-mers;
#SR306286), containing 3 target sequences, were purchased from Origene
(Rockville, MD, USA). LNCaP cells were seeded in 6-well plates (200,000
cells/well) in complete medium (CM) and the transfection was performed the next
day by adding siRNA to the respective wells to a final dose of 5 or 20 nM
following the manufacturer’s protocol. The efficiency of target silencing was
assessed by immunoblotting analysis with anti-Atg5 antibody (Cell Signaling,
#2630). In addition, si-ATG5 treated cells were assayed for the content of LDs by
Oil Red O staining (see below).
Immunoblotting. Cells were lysed and sonicated in RIPA buffer containing
protease inhibitors. Twenty microgram of proteins were separated in each lane
using either 12 or 15% SDS-PAGE and transferred to nitrocellulose membranes.
The membranes were blocked in 5% milk in 1X TBST, incubated with primary
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antibodies, anti-LC3 (MBL, PM036), anti-GFP (Santa Cruz, sc-8334), or anti- actin (Sigma, A1978), and then probed with corresponding goat anti-rabbit or
anti-mouse HP-labeled secondary antibodies (Bio-Rad, Hercules, CA, USA).
LC3-II Translocation assay. LNCaP cells stably transfected with pEGFP-LC3
(LNCaP.EGFP-LC3) were grown on cover slips, washed in 1X PBS and then
incubated in CFM in the presence or absence of R1881 or 3-MA for various time
points, and then observed with a Zeiss immunofluorescence microscope. In
addition, LAPC4 cells were fixed in 4% paraformaldehyde after CDX treatment,
probed with anti-LC3 antibody and then Texas Red labeled goat anti-rabbit
secondary antibody, and observed with a confocal microscope (Zeiss LSM 510).
Distinct puncta and cells were counted from ten random visual fields for each
slide. The number of puncta per cell was used as a measure of autophagic
activity.
Oil Red O staining. Cells were grown on coverslips in indicated medium, fixed in
10% paraformaldehyde, stained with Oil Red O for 15 minutes, and then rinsed in
water. Images were acquired using a brightfield microscope (Zeiss Axioscope).
The numbers of LDs per cell were measured.
Triacylglycerol lipase assay. The amount of intracellular triacylglycerols were
determined using a triacylglycerol assay kit (BioVision, Mountain view, CA, USA).
In brief, cells were harvested, centrifuged and resuspended in 10 ml
corresponding medium. Equal amounts of cells were aliquoted for either

33

triacylglycerol or DNA/protein quantification. The amount of total triacylglycerols
was reported per microgram of DNA or protein from an equal number of cells.
Nuclear Magnetic Resonance Spectroscopy. Three million cells were washed
3 times in PBS prepared with D2O instead of H2O to replace most of the solvent
hydrogen with deuterium. The cell pellets after the final wash were resuspended
in 0.5 ml of DPBS, to which 1 mM DSS was added, and placed into 5 mm NMR
tubes (Wilmad Glass, NJ). Triacylglycerols were extracted from cell pellets by
the method of Folch et al. (162), dried under a stream of nitrogen, dissolved in
0.5 ml CDCl3 containing 0.1 % TMS and placed into 5 mm NMR tubes. Proton
NMR spectra were taken at 37 C (maintained with a VT1000 temperature
controller) with the aid of a Bruker Avance 500 MHz spectrometer running
TopSpin. A 6000 Hz sweep following a 90 pulse was collected into 16K data
points in 1.32 sec with a relaxation delay of 10 sec to ensure that the spectra
resulting from 64 scans were fully-relaxed. The lipid methylene (-CH2-)n signal at

order to measure the intracellular triacylglycerols. The lipid methylene integral
was corrected for the fact that it represented only 84 out of the 104 total protons
from a triacylglycerol molecule containing three assumed oleic acid (n = 14) side
chains as previously described (151).
Co-localization assay. LNCaP.EGFP-LC3 cells were fixed in 4%
paraformaldehyde and stained with HCSLipidTOX Red. Cells were imaged using
a Zeiss LSM 510 confocal microscope with a 63X objective. Images were
analyzed for colocalization of LipidTOX and GFP fluorescence.
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Statistical analysis. Each experiment was performed in triplicate and the data
are presented as the mean ± standard deviation (SD). Data were analyzed by
Student’s t test. A value of P <0.05 was considered statistically significant.
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2.4. Results
2.4.1. Androgen ablation induces autophagy in androgen-sensitive PCa
cells.
To study the effects of androgen deprivation on autophagy and on lipid
droplet degradation in androgen responsive PCa cells, we generated 6
independent clones of LNCaP cells, which we denoted LNCaP.EGFP-LC3,
stably-transfected with pEGFP.LC3. When these clones were grown in complete
medium (CM), the intensities of the EGFP fluorescence in the cytosol were
comparable among the independent LNCaP.EGFP-LC3 clones (Fig. 2.1A, panel
a). Incubation of LNCaP-EGFP.LC3 clones in charcoal-filtered FBS medium
(CFM) induced translocation of EGFP.LC3 from the cytosol to punctate
autophagic vesicles (AVs) (Fig. 2.1A, panel b) and increased the number of AVs
observed per cell by seven-fold (Fig. 2.1B, column b). This effect was due to the
lack of androgens in CFM, because it could be reversed by the addition of the
androgen analogue, R1881 to the CFM (Fig. 2.1A panel c, and Fig. 2.1B, column
c) where the number of AVs returned to that observed (~0.6 per cell) for cells
cultured in CM. Inhibition of autophagy by 3-MA further reduced the formation of
AVs (to ~0.2 per cell) indicating that these are bona fide autophagosomes that
are induced in LNCaP cells during androgen deprivation (Fig. 2.1A, panel d, and
Fig. 1B, column d). In addition, using MTT assay, we showed that blocking of
autophagy by 3-MA induced cell death in LNCaP cells cultured in CFM (Fig.
2.1C), suggesting that autophagy induced by androgen deprivation is prosurvival. This observation is consistent with results previously reported (165,
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166). To confirm that androgen deprivation indeed induced autophagy in LNCaP
cells, we treated cells cultured in CFM with Baf A1, an inhibitor of autolysosome
formation in the final stage of autophagy. There was a greater increase of LC3II
in cells of CFM+Baf A1 (Fig. 2.1D, lane 5) than for cells in CM, CFM, or CM+Baf
A1 (Fig. 2.1D, lanes 1, 2 and 4, respectively), indicating that androgen
deprivation induced autophagy. Interestingly, CDX, an antiandrogen and AR
inhibitor, had no effect on autophagy in LNCaP cells cultured in CM (lane 3). The
basis for this observation is likely due to the mutant AR, which is insensitive to
CDX, in LNCaP cells (165, 166). Consistently, when LNCaP cells were cotreated with CDX and Baf A1 in CFM, we observed a moderate increase of LC3II,
possibly due to the blocking of endogenous autophagy by Baf A1 in LNCaP cells
(Fig. 2.1, lane 6). Moreover, using immunoblot analysis, we found that androgen
deprivation resulting from culture of LNCaP.EGFP-LC3 cells in CFM caused an
increase of EGFP-LC3II (Fig. 2.1E), indicating that autophagy was induced when
hormones were removed.
To confirm that the induction of autophagy during androgen deprivation
was not specific to LNCaP cells, we examined another androgen-sensitive PCa
cell line, LAPC4. Immunofluorescence microscopy analysis using an antibody
against LC3 showed increased AV formation when LAPC4 cells were treated
with CDX for 24 hrs in CM (Fig. 2.2A, panel b), compared to cells in CM alone
(Fig. 2.2A, panel a) or in CFM alone (data not shown). In addition, LAPC4 cells
cultured in CM in the presence of CDX and/or Baf A1 for 24 hrs showed elevated
levels of endogenous, lipidated LC3II and an increase in the ratio between LC3II
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and LC3I (Fig. 2.2B). Moreover, cells cultured in either CFM or CM+CDX for 24
hrs showed a loss of cytosolic p62 (Fig. 2.2C). P62 (SQSTM1/sequestome 1) is
an adaptor protein whose binding to aggregated proteins and organelles tags
them for autophagic degradation. Through binding with the lipidated LC3II
molecules that are localized in the lumenal side of the inner autophagosomal
membrane, p62 sequestomes are selectively and specifically incorporated into
autophagosomes and subsequently degraded by autophagy. Thus, the total level
of p62 inversely correlates with LC3II-dependent autophagic activity, a marker for
autophagic efficiency (163, 164). These data confirm that androgen attenuation
induces autophagy and therefore p62 degradation.
2.4.2. Androgen deprivation reduces the number of lipid droplets in
androgen-sensitive PCa cells.
To investigate the effect of androgen deprivation on lipid droplet (LD)
homeostasis in androgen-sensitive prostate cancer cells, we first showed that
LDs indeed accumulated in LNCaP cells grown in CM (Fig. 2.3A, panel a), as
previously reported (93, 150). The cellular triacylglycerol content was found to
be ~14.5 pM/μg protein (Fig. 2.3C, column a). In contrast to this, cells grown in
androgen-depleted CFM showed at-least a four-fold reduction in the number of
LDs (Fig. 2.3A, panel b) and in the amount of triacylglycerols (Fig. 2.3C, column
b) by day 5, an effect that was reversed by addition of the androgen analogue,
R1881 (Fig 2.3A, panel c; and Fig. 2.3C, column c), or the autophagy inhibitor 3MA (Fig 2.3A, panel d; and Fig. 2.3C, column d). Our observation of a decrease
in lipid droplet formation when androgens are withdrawn is consistent with data
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reported by Swinnen et al. (150). To confirm the effect of androgens on the LD
content, we employed androgen receptor inhibitor, CDX, to block the
androgen/AR axis. The LAPC4 cell line was used for this experiment because it
possesses a wild-type AR. In contrast, it is well documented that the AR gene in
LNCaP is mutated ( 165, 166). LAPC4 cells were cultured in the absence (Fig.
2.3B, panel a) and presence (Fig. 2.3B, panel b) of CDX for 5 days and LD
formation was measured. Oil Red O staining showed a marked reduction in the
number of LDs in the treated cells (Fig. 2.3B, panels b and c; Fig. 2.3D columns
#2 and #3) compared to the control cells grown in CM (Fig. 2.3B, panel a; and
Fig. 2.3D, column #1). In addition, biochemical assays for triacylglycerols also
showed a greater than 70% reduction in intracellular triacylglycerols in the
treated group (Fig. 2.3D, 2nd and 3rd columns). Taken together, these results
show that androgen deprivation depletes LDs in androgen-sensitive PCa cells,
and autophagy inhibitors reverse the phenotype.

2.4.3. siRNA knockdown of ATG5 reverses LD degradation in androgendeprived LNCaP cells.
To determine if autophagy is the causal factor of LD degradation in
LNCaP cells grown in androgen deprivation medium, we treated cells cultured in
CFM with si-ATG5. As shown in Figure 2.4A, immunoblot analysis demonstrated
that 20 nM siATG5 greatly reduced the level of Atg5 expression in cells, as
compared with lipofectamine only or si-Control. Importantly, Oil Red O staining
showed that siATG5 significantly blocked the LD degradation in cells cultured in
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CFM+si-ATG5 (Figure 2.4B), demonstrating that Atg5-dependent autophagy is
essential for androgen deprivation-induced LD degradation.
To confirm that the lipolysis seen in LNCaP cells is not due to artifacts
from the cell manipulation or disruption associated with either the optical or the
biochemical assays, a quantitative NMR method was used to assess the effect of
androgen and 3-MA on triacylglycerol (TG) catabolism in intact LNCaP cells.
Total cellular TGs in treated cells, such as those in Figure 3A and C, were
quantified using proton nuclear magnetic resonance (1H-NMR). Integrals of the
methylene (-CH2-)n signals at 1.29 ppm (as shown in Fig. 2.5, panel a), were
used to calculate the total amount of TGs in each sample, standardized to the
amount of protein in an equal volume of sample. Consistent with the optical
(microscopy) and biochemical (TG enzymatic) assays, 1H-NMR also showed the
reduction of intracellular TGs in cells deprived of androgen (Fig. 2.5, panel b; and
Fig. 2.5E, column b). This effect can be reversed by treatment of the cells with
the androgen analogue R1881 (Fig. 2.5, panel c; and Fig. 5E, column c) or the
autophagy inhibitor 3-MA (Fig. 2.5, panel d; and Fig. 5E, column d).

2.4.4. Autophagosomes colocalize with LDs in LNCaP cells during
androgen deprivation.
To further investigate the role of autophagy in lipid metabolism,
LNCaP.EGFP-LC3 cells were incubated in indicated medium, fixed, stained with
LipidTOX, and observed with a confocal microscope. As shown in Figure 2.6,
EGFP-LC3 (green) was mainly cytosolic and there were abundant LDs (red) in
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cells grown in CM (panels a and b). However, there was almost no colocalization
of EGFP.LC3 and LDs in these cells (panel c; panel n, column 1). However,
when LNCaP cells were cultured in CFM, which lacked androgen, the EGFP.LC3
molecules translocated to green punctate structures, presumed AVs (panel d;
panel m, column 2), which partially colocalized with the red LDs (panels f; panel
n, column 2). The effect of androgen deprivation could be reversed by adding
back the androgen analogue R1881 (panels g to I; panel m, column 3; panel n,
column 3). In addition, blocking the autophagic flux by means of Baf A1 resulted
in a greater accumulation of AVs (panel j; panel m, column 4) and LDs (panel k)
and the number of colocalized AVs and LDs (panel l; panel n, column 4),
indicating that Baf A1 restricted intracellular LD degradation in LNCaP cells.
Panel o showed a representative image of a cell filled with AVs partially
colocalized with LDs, and a magnified image of an LD enwrapped by AVs.
Together, these results show that autophagosomes sequester and target LDs for
lysosomal hydrolysis during androgen ablation in androgen-sensitive PCa cells.
Baf A1, an inhibitor of autophagic flux (131), increased the number of colocalized
AV/LD dots, indicating that Baf A1 restricted intracellular LDs degradation in
LNCaP cells.
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2.5.Discussion
Hormone ablation therapy is a standard treatment for initially androgensensitive prostate cancers. Unfortunately, these tumors generally progress in
time to an androgen independent phenotype by activating various cellular
pathways for survival in an androgen-depleted environment (19, 167) and then
this treatment is no longer useful. Because metabolic deregulation is commonly
observed during tumoriogenesis, we sought to determine if alternate metabolic
pathways were activated during the adaptation of prostate cancer cells to
androgen deprivation. We confirmed that either culturing cells in an androgen
deprived medium, or inhibiting the wild-type AR, induced autophagy and cell
death in androgen-sensitive PCa cell lines. Moreover, we found, using
histochemical, biophysical and biochemical techniques, that the inhibition of
autophagy resulted in the retention of cytoplasmic lipid droplets in these cells.
We further found that autophagosomes colocalized with LDs. Inhibiting the
autophagic lysosomal degradation of the lipid droplets by using Bafilomycin A1 or
si-ATG5 also caused retention of intracellular triacylglycerols. These findings
show that, in the absence of androgens, autophagy was activated in androgensensitive PCa cells with the consequence that LDs were sequestered and
targeted to the lysosomes for hydrolysis. Activation of this alternate pathway of
lipolysis during androgen ablation could be a critical event supporting the survival
and progression of prostate tumors into an androgen-independent phenotype.
Even though autophagy has been found to be activated during a variety of
treatments for different cancer types (35, 40, 44, 47), its role in the survival or
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death of prostate cancer cells has not been extensively examined. What is
known is that radiation therapy of PCa cells induced cytoprotective autophagy
(44) and that incubation of LNCaP cells, but not PC3 cells (an androgeninsensitive PCa line) in serum free medium induced autophagy (49, 157). Li and
colleagues also reported that the inhibition of autophagy led to increased
apoptosis of LNCaP cells in serum free medium compared to medium containing
either dihydrotestosterone or serum, suggesting that autophagy protects LNCaP
cells during androgen deprivation (49, 157). Studies using other tumor cell types
have shown that growth factors in serum are potential regulators of autophagy
through activation of the mTOR pathway, which is an inhibitor of autophagy
(168). We induced autophagy in LNCaP and LAPC4 cells through androgen
deprivation by using charcoal-filtered serum medium, and in LAPC4 cells by
growing them in the presence of the antiandrogen, casodex (CDX) (Figure 2.1).
Interestingly, however, CDX did not affect autophagy in LNCaP cells, in which
the AR gene is mutated. It has been reported that CDX stimulated the mutant AR
(165, 166), which may be the reason that LNCaP cells were insensitive to CDX
treatment.
Prostate cancer cells have a unique intermediary metabolism that
markedly differs from that found in other cancer cell types (94, 107). Otto
Warburg found that most cancer cells rely primarily on aerobic glycolysis to
generate ATP to meet their energy demand (97, 99). However, glucose does not
play a major metabolic role in androgen-dependent PCa cells because LNCaP
cells can grow with a medium glucose concentration as low as 0.28 mM (94,
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169). Importantly, androgens stimulate both the lipogenic and fatty acid βoxidation pathways in androgen-dependent PCa cells to fulfill their increased
bioenergetic needs (14, 93, 94, 107, 118, 151, 152). Recently, Singh and
colleagues reported that autophagosomes sequestered LDs and mediated
lysosomal lipolysis in rat hepatocytes (83). This increased delivery of LDs to the
lysosome by autophagosomes was observed under conditions of starvation or
lipid overload. We found that this novel function of autophagy also serves as an
alternate pathway for lipolysis in androgen-sensitive PCa cells during androgen
deprivation: Incubation of LNCaP cells in CFM significantly reduced the amount
of LDs by day 6 (Figures 2.3A, 2.3C, 2.4 and 2.5e), which is consistent with
results previously reported (150). The same result was observed in LAPC4 cells
when androgens were depleted using CFM or the AR was inhibited with CDX
(Figure 2.3B and 2.3D). In addition, 3-MA, a phosphatidylinositol-3-kinase
inhibitor used extensively to block autophagosome formation at the initiation
phase, blocked autophagosome formation and inhibited autophagy and therefore
LD degradation in LNCaP cells (Figures 2.1, 2.3 and 2.4). All three independent
methods to measure LDs or their major constituent triacylglycerols showed that
inhibition of autophagy caused retention of LDs indicating that autophagosomes
play a role in the metabolism of LDs (Figures 2.3 and 2.4). We further showed
that autophagosomes colocalize with LDs by using fluorescent microscopy. On
average, 1.5 LDs were observed to colocalize with autophagosomes per cell.
Treatment of LNCaP cells with Bafilomycin A1 (Baf A1) has been reported to
inhibit lysosomal acidification/hydrolysis, to block autophagic degradation, and to
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cause the accumulation of autophagosomes (131). In our study, the treatment of
LNCaP cells with Baf A1 indeed led to the accumulation of autophagic vesicles
and increased the amount of colocalization of them with LDs (Fig. 2.6, panels j, l
and o; column 4 of panels m and n). We also measured intracellular
triacylglycerols after the inhibition of autophagic degradation in both LNCaP and
LAPC4 cells. For example, LAPC4 cells treated with Baf A1 for 24 hours under
conditions of androgen deprivation led to an increase in the amount of TGs
compared to cells grown only under androgen deprivation (Figure 2.3D, column
3). These data indicated that autophagosomes sequestered and targeted LDs to
the lysosome in androgen-sensitive PCa cells when androgens were absent.
Lysosomal lipases are known to hydrolyze triacylglycerols into glycerols and fatty
acids (85, 88), and these fatty acids can either be translocated to peroxisomes
and mitochondria for β-oxidation for energy production or used for new
membrane synthesis for proliferation. The existence of an alternate pathway of
lipolysis in PCa cells may help to explain how androgen responsive PCa cells
adapt to survive in the absence of the key metabolic regulator, androgens.
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2.7. Figures and figure legends:

Figure 2.1. Androgen deprivation induces autophagy in LNCaP cells, which
can be reversed by autophagy inhibitors, 3-MA and Bafilomycin A1 (Baf
A1). A. LNCaP.EGFP-LC3 cells (LNCaP cells stably transfected with
pEGFP.LC3) were incubated for 2 days in indicated medium, (a) CM, complete
medium; (b) CFM, charcoal-filtered fetal bovine serum medium; (c) CFM+R1881;
and (d) CFM+3-methyladenine (3-MA). Cells were mounted in coverslips and
observed with a Zeiss LSM 510 confocal microscope. B. Numbers of cells and
puncta were counted from 10 random visual fields for each group. Average
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numbers of puncta per cell were plotted in the graph. C. Blocking autophagy by
3-MA, an inhibitor of the initial stage of autophagy, induced cell death in LNCaP
cells cultured in CFM by day 4, as analyzed by MTT assay. D. Induction of
autophagy was confirmed in LNCAP cells treated with CFM. Immunoblot analysis
showed that treatment of Baf A1, a blocker of the autolysosome formation in the
final stage of autophagy, in cells cultured in CFM resulted in greater increase of
LC3II (lane 5) compared to cells cultured in CM (lane 4), indicating that androgen
deprivation induced autophagy. CDX, an AR inhibitor, showed no effect on LC3 II
level and thus autophagy in LNCaP cells cultured in CM (lane 3), whereas
combinational treatment of CDX and Baf A1 showed moderate increase of LC3II, suggesting that the endogenous autophagy is inhibited by BAf A1. E. Timedependent activation of autophagy in LNCaP.EGFP-LC3 cells cultured in
medium CFM. Immunoblot analysis showed that the level of EGFP-LC3II (45
kDa) was increased in a time-dependent manner in cells grown in CFM.
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Figure 2.2. Androgen antagonist CDX induces autophagy in LAPC4
cells. A. LAPC4 cells were incubated for 24 hrs in (a) CM or (b) CM + 5
M casodex (CDX). Cells were mounted in coverslips, probed with anti49

LC3 antibody and then Texas Red labeled goat anti-rabbit secondary
antibody, and observed under a Zeiss immunofluorescence microscope.
There was a marked increase in LC3II-containing punctate structures,
presumed to be autophagic vesicles (AVs; Fig. 2A, panel b). B. LAPC4
cells were incubated for 24 hrs in (lane 1) CM; (lane 2) CM+5 M CDX;
(lane 3) CM+ 100 nM bafilomycin A1 (Baf A1), an inhibitor of autophagic
flux; or (lane 4) CM+CDX+Baf A1. Immunoblot analysis showed that levels
of LC3II were increased in cells treated with CDX or Baf A1 (lanes 2 and
3), and an additive effect on LC3II activation when cells were treated with
CDX and Baf A1 (lane 4). The ratios of LC3II/LC3I are 0.1, 0.25, 0.4 and
0.6, corresponding to lane 1, 2, 3, 4, respectively. C. Immunoblot analysis
showed that p62, a marker of effective autophagy, was markedly
downregulated in LAPC4 cells treated with androgen deprivation (CFM;
lane 2) or androgen antagonist CDX (lane 3), suggesting that androgen
attenuation induces autophagy and therefore p62 degradation.
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Figure 2.3. The crosstalk between androgen, autophagy and lipid droplets
in androgen sensitive PCa cells. A. LNCaP cells were incubated for 5 days in
indicated medium, (a) CM, complete medium; (b) CFM (c) CFM+R1881, and (d)
CFM+3MA. Cells were stained with Oil Red O, mounted in coverslips, and
observed with a Zeiss Axioscope brightfield microscope. Androgen deprivation in
CFM (b) caused depletion of lipid droplets in LNCaP cells, which could be
reversed by adding back androgen (R1881; c) or blocking autophagy with 3-MA
(d). B. LAPC4 cells were incubated for 5 days in indicated medium, (a) CM, (b)
CM+CDX, and (c) CM+CDX+3-MA. Cells were stained with Oil Red O, mounted
in coverslips, and observed with a Zeiss Axioscope brightfield microscope.
Inhibition of the AR by CDX induced depletion of lipid droplets (panel b), whereas
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3-MA, an inhibitor of PI3K and therefore autophagy, reversed the CDX effect on
lipid droplets (panel c). C, the quantitative assay of intracellular triacylglycerols in
LNCaP cells described in A. D. the quantitative assay of intracellular
triacylglycerols in LAPC4 cells cultured in CM, CM+CDX and CM+CDX+Baf A1.
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Figure 2.4. Attenuation of autophagy by Si-ATG5 retains LDs in androgendeprived LNCaP cells. A. Si-ATG5 knockdown of Atg5 was confirmed by
immunoblot analysis. Twenty μg of total soluble protein extracts were used from
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cells cultured in CM in the presence of lipofectamine (lipofect.), si-Control, and 5
and 20 nM si-ATG5. B. Treatment of Si-ATG5 (20 pM) blunted CFM-induced LD
degradation. Oil Red O staining indicated that siRNA knockdown of ATG5
restored LD content in cells cultured in CFM (panel 4). All the stained images
were taken with the same microscope (Zeiss A1) with a CCD camera
(Optronics), and the same parameters.
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Figure 2.5. Quantitative NMR assay of the effect of androgen and 3-MA on
triacylglycerols in LNCaP cells. Total cellular triglycerides in treated cells were
quantified using proton nuclear magnetic resonance (1H-NMR). All cells were
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cultured in (a) CM; (b) CFM; (c) CFM+R1881, CFM for 3 days and then treated
with R1881 for another 3 days; and (d) CFM+3-MA, CFM for 3 days and then
treated 3-MA for another 3 days. On day 6, cells were washed, trypsinized &
harvested. Integrals of the methylene (-CH2-)n signals at 1.29 ppm are typical
examples of which were used to calculate the total amount of triglycerides in
each sample and standardized to the amount of protein in an equal volume of
sample used for NMR spectroscopy. The bar graph (e) shows the averages for n
= 3 measurements for each treatment.
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Figure 2.6. Autophagosomes colocalize with LDs in LNCaP cells during
androgen deprivation. LNCaP.EGFP-LC3 cells were incubated for 3 days in
indicated medium, (a) CM, (d) CFM; (g) CFM+R1881, and (j) CFM plus BAF A1
for 12 hours. Cells were fixed, stained with HCSLipidTOX Red, and observed
with a Zeiss LSM 510 confocal microscope. Panels of EGFP.LC3 (green), of
LipidTOX (red) and merged are as indicated. Colocalization of autophagic
vesicles (AVs; green) and lipid droplets (red) were yellow dots shown in the
merged panels. In CM, EGFP-LC3 was mainly cytosolic and there were
abundant LDs in cells (panels a and b). There was almost no colocalization of
EGFP.LC3 and LDs in these cells (panel c; column 1 in panel n). However, when
cells were cultured in CFM, which lacked androgen, the EGFP.LC3 molecules
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translocated to green punctate structures, presumed AVs (panel d; column 2 in
panel m), which partially colocalized with the red LDs (panels f; column 2 in panel
n). The effect of androgen deprivation could be reversed by adding back R1881
(panels g to I; column 3 in panels m and n). In addition, blocking the autophagic
flux by Baf A1 resulted in a greater accumulation of AVs (panel j; column 4 in
panel m) and LDs (panel k) and the number of colocalized AVs and LDs (panel l;
column 4 in panel n), indicating that Baf A1 restricted intracellular LD degradation
in LNCaP cells. Panel o showed a representative image of a cell filled with AVs
partially colocalized with LDs, and a magnified image of a LD enwrapped by AVs
(inset).
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3.1. Abstract
Modulation of autophagy is a new paradigm in enhancing the therapeutic
efficacy of various cancer treatments. Recently, a novel function of chloroquine in
inhibiting degradation of autophagic vesicles has led to studies on cancer cells
whether chloroquine can be used as an adjuvant in targeting autophagic
prosurvival mechanism. We previously observed that autophagy plays a
protective role during hormone ablation therapy in prostate cancer cells by
consuming lipid droplets. Here, to further investigate the importance of
autophagy in PCa cell survival and dissect the role of CLQ in PCa cell death, we
treated hormone responsive LNCaP cells with chloroquine during androgen
deprivation. We observed that chloroquine synergistically kills LNCaP cells
during androgen deprivation in a dose and time dependent manner. We further
confirmed that chloroquine inhibits the maturation of autophagic vesicles and
decreases the cytosolic ATP. Moreover, chloroquine induces apoptosis in
androgen deprived LNCaP cells. Our finding suggests that chloroquine may be
useful as an adjuvant in hormone ablation therapy to improve the therapeutic
efficacy.
Keywords: Prostate cancer, Chloroquine, Androgen deprivation, Autophagy
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3.2. Introduction
Prostate cancer (PCa) is the most common cancer among men of all races
in the United States (1, 3, 4). About 1 in 6 men will be diagnosed of PCa in his
lifetime. There are three standard types of treatment in prostate cancer: surgical
resection, radiation therapy and hormone ablation therapy. In general, surgical
resection and radiotherapy are conducted when the tumor is localized (3, 5).
However, once metastasized, prostate tumors are hard to cure and bear poor
prognosis (3, 5, 6). It is well known that androgens are essential for survival,
proliferation, and progression of PCa cells (8, 21). Androgen ablation induces
apoptosis and regression of hormone responsive PCa cells (153, 154). Thus,
hormone ablation therapy is a treatment option when PCa cells metastasize (5).
However, unfortunately, some PCa cells can escape and survive the treatment
and subsequently develop hormone/castration resistant phenotype (19, 20).
Developing adjuvant therapy that would enhance the therapeutic effectiveness of
hormone ablation therapy is crucial for PCa treatment.
We previously reported that during hormone ablation therapy, autophagy is
induced in two different hormone sensitive PCa cell lines, LNCaP and LAPC4
cells (chapter 2). Autophagy is a cytosolic mechanism in which a portion of the
cytosol constituents including aberrant organelles is enwrapped by newly formed
vesicles, known as autophagic vesicles and targeted to lysosomes for hydrolysis
(22, 45). These autophagic vesicles (AVs) can be induced during androgen
deprivation and can sequester lipid droplets, a mechanism known as lipophagy
(85-88). As PCa cells are rich in lipid droplets and rely predominantly on β61

oxidation for their bioenergetic needs, this alternate pathway of lipolysis is crucial
for their survival during hormone ablation therapy (94, 118). Inhibition of
autophagy by 3-Methyladenine (3-MA) significantly killed more cells growing in
the absence of androgen than cells growing in regular medium, suggesting that
autophagy protects LNCaP cells during androgen deprivation (chapter 2). Similar
results were reported in two other studies where genetic knockdown of
autophagy caused more cell death in the absence of androgen (49, 157).
Modulation of autophagy in cancer treatment is a new and exciting field. It
has been shown that inhibition of autophagy by either 3-MA or Chloroquine
(CLQ) sensitizes LNCaP cells to Src kinase inhibitors such as saracatinib and
PP2 (148). 3-MA is a PI3 kinase inhibitor which blocks the early stage of
autophagosome formation, whereas CLQ is a lysosomotropic drug which inhibits
the autolysosomal degradation (146). CLQ causes accumulation of AVs but
prevents its major function, i.e. breaking down the cytosolic and vesicular
components for recycling of biomolecules for energy generation. CLQ has been
used widely as an effective antimalarial and anti-rheumatoid drug (135). Recent
studies have been conducted to seek CLQ as an adjuvant in different cancer
therapies. CLQ has been shown to potentiate the cytotoxic effects of 5fluorouracil in colon cancer cells (146). Combining CLQ with Akt inhibitors also
significantly enhanced the cell death effect in breast cancer cells (170). CLQ also
potentiated the efficacy of carmustine on glioma cells in vivo and in vitro (171).
Taken together, these reports suggest that CLQ is a potential candidate to
enhance the anti-cancer effect of hormone ablation therapy in PCa. As
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autophagy induced during androgen ablation helps to protect LNCaP cells, we
hypothesized that CLQ augments the apoptotic effect of androgen deprivation in
LNCaP cells. We treated LNCaP cells with CLQ in the presence or absence of
androgen and characterized the cell death effects and pathways that were
activated.
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3.3. Materials and Methods
Chemicals and reagents. Charcoal-filtered fetal bovine serum (CFM) was
purchased from Hyclone (Thermo Fisher, MA, USA), RPMI 1640, and regular
FBS was from Gibco/Invitrogen (Eugene, OR, USA). Chloroquine diphosphate
salt was purchased from Sigma Aldrich (St Louis, MO, USA) and dissolved in
dH2O. Trihydrochloride trihydrate was purchased from Molecular Probe (Eugene,
OR, USA).
Cell culture and transfection with pEGFP-LC3. Human prostate cancer cells
LNCaP (American Type Culture Collection, Manassas, VA) were grown in RPMI
1640 medium with 10% (v/v) fetal bovine serum (FBS) at 37 0 C and 5% CO2.
pEGFP-LC3 stably transfected LNCaP cell lines were generated as described in
chapter 1. Cells were grown in CM or CFM in the presence or absence of CLQ at
the indicated concentrations.
Cell viability assay. LNCaP cells were seeded in equal number (10,000 cells/
well) in 96 well plates and cultured in CM or CFM overnight. CLQ was added at
200 uM and incubated for 24 hours or other time points where specified. The cell
viability was then examined by using 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay according to manufacturer’s
instructions (Vybrant MTT assay, Invitrogen, Eugene, OR, USA).
LC3-II translocation assay. LNCaP cells stably transfected with pEGFP-LC3
(LNCaP.EGFP-LC3) were grown on cover slips, washed in 1X PBS and then
incubated in CM or CFM in the presence or absence of CLQ for 24 hours, and
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then observed under the LSM 510 confocal microscope. Number of cells and
distinct puncta were counted from ten random visual fields for each slide. The
number of puncta per cell was used as a measure of autophagic activity.
ATP measurement. Equal number of LNCaP cells (10000 cells/ well) were
seeded in 96 well plates and incubated in CM or CFM. Cells were treated with
CLQ (200 uM) for 24 hours. Intracellular ATP levels were measured using a
colorimetric assay kit (Abcam, San Francisco, CA, USA) followed the
manufacturer’s instruction.
Annexin-V/PI assay. Cells were treated with CLQ for 36 hours in CM or CFM.
Both, the floating cells and the attached cells were harvested. Cell pellets were
washed twice with 1X DPBS and then resuspended in 1X Binding buffer at a
concentration of 1 x 106 cells/ ml. One hundred μl of the suspension (1x105 cells)
was used to label with Annexin V- FITC and Propodium Iodide (BD Biosciences,
San Diego, CA, USA) and analyzed by flow cytometry.
DNA fragmentation assay. LNCaP cells were seeded in equal number and
cultured in CM or CFM and then treated with CLQ for another 36 hours. The
floating cells were collected, washed with ice-cold DPBS, lysed with lysis buffer
[10 mM Tris (pH 7.4), 5 mM EDTA, and 1% Triton X-100] for 20 min on ice, and
centrifuged at 11000 x g for 20 min. The supernatant was collected and treated
with RNase A and Proteinase K for 1 hour at 370 C. DNA was extracted using
phenol-chloroform method, resuspended in equal volume of 1 x TE, and then
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electrophoresed in 0.8% agarose gel. DNA was visualized using Ethidium
Bromide staining.
Hoechst nuclear staining. LNCaP cells were inoculated on coverslips in 6 well
plates, cultured, and treated with CLQ for 36 hrs as in DNA fragmentation assay.
Attached cells were washed and stained with Hoechst 33342 and observed
under a Zeiss Axioskop microscope.
Statistical analysis. Each experiment was performed in triplicate and the data
are presented as the mean ± standard deviation (SD). Data were analyzed by
Student’s t test. A value of P <0.05 was considered statistically significant.
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3.4. Results
3.4.1. Chloroquine synergistically kills LNCaP cells during androgen
deprivation.
To study the effect of CLQ on the survival of LNCaP cells, ten thousands
cells were seeded in 96 well plates in regular medium (CM) or androgen deprived
medium (CFM). Both groups were treated with increasing concentrations of CLQ
(0 -600 μM) for 24 hours. Viable cells were quantified using MTT assay. The
cytotoxicity of CLQ was observed that was correlated with concentrations of CLQ
in both conditions (Figure 3.1). When cells were treated with 200 μM of CLQ for
24 hours, there was little effect on cells grown in CM, whereas there was 15%
reduction in cell grown in CFM. At higher concentrations, CLQ has greater
cytotoxicity in cells treated with androgen deprivation.
Because CLQ has a long half life (t1/2= 2- 6 days) (135, 138), we looked at
the time dependent effect of CLQ during androgen deprivation. Treatment of
LNCaP cells with CLQ at 200 μM for 2 days in CFM reduced the number of
viable cells by 30%, whereas treatment for 3 days reduced the number by more
than 50% compared to cells growing in the CFM only (Figure 3.2 A & B).
3.4.2. Chloroquine blocks autophagic degradation and reduces cytosolic
ATP in LNCaP cells.
To investigate if CLQ affected the maturation of autophagic vesicles, we
incubated LNCaP.EGFP-LC3 cells with CLQ (200 μM) in the presence or
absence of androgen. We previously showed that incubation of LNCaP cells in
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CFM induces translocation of cytosolic EGFP-LC3 to puncta like autophagic
vesicles. As shown in Figure 3.3, CLQ also induced increase of puncta in cells
cultured in CM; however the accumulation of puncta was even greater in cells
cultured in CFM, suggesting that CLQ blocks degradation of autophagic vesicles
(Figure 3.3 A, panel c & d).
To study the effect of CLQ on bioenergetics, the cytosolic ATP was
measured in LNCaP cells treated with CLQ in CM or CFM. Interestingly, without
CLQ, there was no change in the amount of ATP in cells cultured in CM and
CFM (Figure 3.3 B, column c and a). However, CLQ alone decreased the
cytosolic ATP by 20% in cells growing in CM (Figure 3.3 B, column b), whereas
combinational treatment of CLQ and CFM decreased the cytosolic ATP level by
38% (Figure 3.3 B, column d), suggesting that autophagy dependent metabolism
is more prominent in androgen deprived LNCaP cells.
3.4.3. Chloroquine induces apoptosis in LNCaP cells.
To characterize the cell death pathway during CLQ treatment, cells were
incubated in CM or CFM in the presence or absence of CLQ. Cells were
harvested at 36-hr time point and labeled using Annexin V-FITC and propodium
iodide co-staining, and analyzed by flow cytometry. We observed that androgen
deprivation or CLQ treatment alone has a little effect on apoptosis (Figure 3.4 A,
panel b & d), whereas CLQ synergistically increased apoptotic cells in cells
cultured in CFM (Figure 3.4 A, panel c).
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To further confirm that CLQ induced apoptosis during androgen
deprivation, we investigated DNA laddering and chromatin condensation, two
other hallmarks of apoptosis. DNA was fragmented in laddered pattern from cells
treated with CLQ and CFM (Figure 3.4 B, third lane), but not from cells treated
with CLQ or androgen deprivation alone. Further, combined treatment of LNCaP
cells with CLQ and androgen ablation caused significant alterations in nuclear
morphology, known as nuclear condensation/fragmentation (Figure 3.4 C, panel
C). The nuclei were in crescent shape and looked fragmented.
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3.5. Discussion
In this study, we showed that combinational treatment of chloroquine and
androgen deprivation has better efficacy in killing LNCaP cells: CLQ
synergistically kills in a dose and time dependent manner with androgen
deprivation in LNCaP cells. We also observed that CLQ blocked the degradation
of autophagic vesicles. Furthermore, we confirmed that autophagy is important
for the generation of bioenergetic precursors as CLQ treatment lowered the
cytosolic ATP. Moreover, CLQ treatment enhanced the apoptosis in androgen
deprived LNCaP cells, as evidenced by Annexin V-FITC/ PI analysis, DNA
laddering and nuclear staining.
CLQ has been used to treat different diseases (for e.g. malaria,
rheumatoid arthritis and lupus) for more than 60 years (135, 136, 137). The
application of CLQ as an adjuvant in cancer therapy has emerged because it can
work as a weak intercalating agent and halt the DNA repair process (139). This
function has been found useful in potentiating the killing effect of radiated cancer
cells (135). CLQ is a weak base that would be widely distributed in human body if
administrated. In its unprotonated form, CLQ can diffuse through the plasma
membrane. However, when CLQ is in the acidic organelles like late endosomes,
and lysosomes, it is protonated and trapped inside the lumen of the organelles
(135, 138, 140). This causes increase in the pH which inactivates the lysosomal
hydrolases, and thus lysosomal function. CLQ caused inhibition of maturation of
autophagic vesicles and accumulation of autolysosomes in several types of
human cells (138, 140-144).
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Effects of chloroquine on maturation of autophagic vesicles are potentially
important in cancer therapies where cells induce autophagy as a pro-survival
mechanism. In HT-29 colorectal cancer cells, treatment with 5-fluorouracil (5-FU)
induces autophagy, however, in the presence of CLQ, autophagosomal
degradation is inhibited and therefore potentiates the anti-cancer effect of 5-FU
(146). In another study, CLQ induces dose dependent cell death in 5 different
glioblastoma cell lines independent of p53 status suggesting that CLQ also
affects cell death beyond its effect in DNA repair process. Furthermore, they
found that CLQ induces accumulation of autophagic vesicles in the cell lines they
studied and affects the levels and subcellular distribution of Cathepsin D (147).
These findings suggest that altered lysosomal function may play a role in CLQinduced cell death. Inhibition of autophagy by CLQ also sensitizes prostate
cancer cells to Src family kinase inhibitors like saracatinib and PP2 (148). It has
been shown that Src kinase inhibitors induce autophagy in both LNCaP and PC3
cells. Inhibition of autophagy by CLQ, 3-MA or si-Atg7 during Src kinase
inhibitors treatment, more cell death was observed.
We and others demonstrated that autophagy is induced in hormone
sensitive prostate cancer cells either by incubation in androgen deficient medium
or treatment of an androgen inhibitor, Casodex. Chemical inhibition of autophagy
by 3-MA or genetic ablation of autophagy machinery (si-Beclin 1, si-Atg 5) causes
more cell death, suggesting that autophagy protects PCa cells during androgen
deprivation. We also observed that one survival mechanism of autophagy is to
sequester lipid droplets and target to lysosomes for the generation of precursors
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for cellular bioenergetic needs. Lysosomes are cellular digestive organelles where
acidic hydrolases degrade complex biological molecules and help in recycling of
biomolecules (85-87). Autophagy is well known to mediate recycling of
biomolecules inside the cells during starvation. It starts with sequestration of a
portion of the cytosol with organelles in a double or multilayered vesicle which then
fuses with lysosomes. As CLQ alters the function of lysosomes, it inhibits
autophagosomal degradation and causes accumulation of autophagic vesicles
(146). Here, we showed that CLQ causes accumulation of autophagic vesicles in
androgen deprived LNCaP cells. Accumulation of autophagic vesicles in LNCaP
cells was also observed when cells were treated with H+ V+ ATPase inhibitor,
Bafilomycin A1 (chapter 2). CLQ also caused accumulation of AVs in the presence
of androgen, but less in the amount than in the cells grown in androgen deprived
medium. This is consistent with our earlier finding that basal autophagy is active in
LNCaP cells (chapter 2). Moreover, CLQ causes reduction in cytosolic ATP level,
suggesting that autophagy is important for regenerating bioenergetic fuels during
androgen deprivation. Interestingly, inhibition of autophagy by CLQ induces
apoptosis in LNCaP cells. During apoptosis in CLQ treated LNCaP cells, there was
a change in nuclear morphology and DNA fragmentation. These results are
consistent with other reports that autophagy inhibition by CLQ induces cell death in
a variety of cancer cell types.
Hormone ablation therapy is a major treatment modality in PCa (5).
However, it relapses as hormone/castration resistant phenotype in many patients
by some poorly defined mechanisms (17-21). We speculate that the effect of
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hormone ablation therapy may be potentiated and synergized by inhibiting one of
the cancer survival mechanisms. Chloroquine is a drug already in clinical usage,
repurposing it as an adjuvant in hormone ablation therapy is practical and cost
effective. Further study in pre-clinical trial is warranted in animal models of
hormone sensitive PCa that is required to test the efficacy and efficiency of CLQ
in vivo.
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3.7.Figures and figure legends

Figure 3.1: Survival effect of chloroquine (CLQ) on LNCaP cells. Cells were
incubated in the presence (CM) or absence of androgen (CFM). CLQ was added
at increasing concentration (0-600 uM) and treated for 24 hours. Viable cells
were quantified by MTT assay.
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Figure 3.2: Time dependent effect of CLQ on the proliferation of LNCaP
cells. A. Equal number of cells were seeded and incubated in CM or CFM. CLQ
(200 μM) was added and treated for 1 day, 2 days and 3 days. Viable cells were
quantified by using MTT assay at each time point. B. Microscopic view of cells
from day 1 and day 3 from the same experiment.
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Figure 3.3: Effect of CLQ on autophagic vesicles. A. LNCaP.EGFP-LC3 cells
were incubated in CM or CFM as indicated. CLQ (200 μM) was added in the
medium and incubated for 24 hours. Cells were fixed and observed under
confocal microscope. B. Intracellular ATP level was measured in LNCaP cells
treated as above.
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Figure 3.4: CLQ treatment induces apoptosis in LNCaP cells during
androgen deprivation. A. Cells were incubated in CM or CFM and treated with
chloroquine (200 μM) for 48 hours. Cells were harvested and labeled with
Annexin-V-FITC and PI and analyzed by flow cytometer. The lower right
quadrant of each group represents the percentage of cells undergoing apoptosis.
B. Cells grown on coverslips were treated with CLQ (200 uM) in CM or CFM for
36 hours. The attached cells were stained with Hoechst nuclear stain and
observed under microscope. B. DNA laddering assay of cells treated with
chloroquine. Equal number of cells were seeded and treated as indicated for 36
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hours. DNA was extracted from cells floating in the medium (dead cells) and
separated in 0.8% agarose gel.
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Chapter 4

Discussion and Future Perspectives
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4.1 Autophagy in hormone sensitive Prostate cancer cells during
androgen deprivation
The function of autophagy in the pathogenesis of cancer is an exciting yet
under-studied field. Autophagy can be activated during a variety of treatments in
different cancer types. However, its role in the tumorigenesis and effects in
various Prostate cancer (PCa) therapies are less studied.
As hormone ablation therapy is common in PCa treatment, we seek to
determine the fate of autophagy in hormone sensitive PCa cells. Previously, it
was shown that incubation of LNCaP (androgen sensitive), but not PC-3 cells
(androgen insensitive), in serum free medium induced autophagy (49).
Androgens may inhibit autophagy which is supported by the observation that
addition of the androgen analogue DHT inhibited autophagy in LNCaP cells. That
result was consistent with earlier reports that increased autophagic vesicles were
observed in prostate epithelial cells from castrated mice (50). Studies using
other tumor cell types have shown that growth factors in serum are potential
regulators of autophagy through activation of the mTOR pathway, which is a
negative regulator of autophagy (48). Thus, we sought to further investigate the
autophagy induction during androgen deprivation by using a charcoal-filtered
serum containing medium (CFM). Charcoal filtration removes the steroid
hormones out from the serum, but not other growth factors. We confirmed that
incubation of LNCaP cells in CFM induces autophagy, which was abrogated by
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the addition of androgen analogue, R1881. Increased translocation of cytosolic
EGFP.LC3 to puncta-like structures was observed by confocal microscopy.
Immunoblot analysis also showed increased autophagic flux during androgen
deprivation. However, we did not observe autophagy induction in LNCaP cells in
the presence of androgen antagonist, bicalutamide (CDX) in normal medium. It
has been documented that the LNCaP cell line carries mutations in the androgen
receptor (AR) gene (165, 166). Instead, CDX has been shown to stimulate the
activity of mutant AR, which may be the reason that LNCaP cells were insensitive
to CDX treatment.
To confirm that the induction of autophagy during androgen deprivation is
not specific to LNCaP cells, we examined another hormone sensitive PCa cell
line, LAPC4, which is known to have wild type AR. Immunofluorescence
microscopy using an antibody against LC3 showed increased formation of
autophagic puncta structures when LAPC4 cells were treated with CDX.
Immunoblot analysis of LC3 expressions (ILC3II/LC3I) also showed increased
autophagic flux. To further confirm this observation, we carried out Western blot
analysis of p62 in LAPC4 cells. p62 is a cytosolic protein that is degraded by
autophagy and is commonly used to measure the autophagic flux. Treatment of
LAPC4 cells with CDX resulted in the loss of cytosolic p62. These results
confirmed that autophagy is induced in two different hormone sensitive PCa cells
during androgen deprivation.
Li et al have shown that inhibition of autophagy during incubation of
LNCaP cells in serum free medium caused increased cell death (49)). In these
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experiments, autophagy was inhibited by both pharmacological and genetic
means. Addition of an androgen analog rescued the effect on cell death effect
seen on incubation in serum-free medium, suggesting the protective role of
autophagy during this treatment. When we treated the LNCaP cells grown in
CFM with 3-MA, a significant reduction in cell number was observed compared to
the non-treated group, which further confirmed the protective role of autophagy
during androgen deprivation.

4.2. Autophagy regulated lipolysis in Prostate Cancer cells
One of the main goals of the present study was to elucidate the effects of
autophagy on cell survival that was observed during androgen deprivation. In
Chapter 2 we showed that autophagy regulates lipolysis through degradation of
lipid droplets in androgen sensitive PCa cells. We first confirmed that LNCaP and
LAPC4 are enriched in lipid droplets. Incubation of LNCaP cells in androgendeprived medium significantly lowered the number of intracellular lipid droplets
and triglycerides by 80%, which was reversed by the addition of the androgen
analogue R1881. However, androgen inhibitor CDX had no effect on lipid
droplet content in LNCaP cells. Therefore, we chose to use LAPC4 cells which
carry the wild type AR, to further explore the co-relationship between autophagy
and lipolysis. We observed 70% reduction in intracellular triglycerides by day 5
on treatment of LAPC4 with CDX.
To evaluate the effect of autophagy on lipolysis, we inhibited autophagy
with 3-MA and quantified the intracellular levels of lipid droplets or triglycerides
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using three different methods (biochemical, biophysical and histochemical) in
LNCaP cells. All three methods showed that autophagy inhibition during
androgen deprivation caused partial retention of lipid droplets. Consistent with
this, retention of lipid droplets was also observed when autophagy was inhibited
by siRNA. To further confirm these observations, we inhibited autophagy in
LAPC4 cells using 3-MA. Oil Red O staining showed that depletion of lipid
droplets by CDX treatment was reversed on the addition of 3-MA. Taken
together, these results suggest that autophagy plays a role in lipolysis in
hormone sensitive PCa cells.
To further investigate the role of autophagy in lipid metabolism, we
stained LNCaP cells stably expressing pEGFP-LC3 with the neutral lipid dropletspecific fluorescent dye, HCS LipidTOXTM Red. Confocal microscopy images
showed that the green puncta from the EGFP-LC3 molecules colocalized with
the red puncta from LipidTOXTM when androgen was withdrawn. The degree of
colocalization was enhanced when Bafilomycin A1 was added to the medium,
suggesting that autophagosomes sequester and target lipid droplets for
lysosomal hydrolysis during androgen ablation in hormone sensitive PCa cells.
Furthermore, quantification of triglycerides in Bafilomycin A1 treated LNCaP and
LAPC4 cells showed retention of lipid droplets in both cell lines.
PCa cells have a unique intermediary metabolism (2). Contrary to many
other types of solid tumors, they use lipid metabolism for their increased
bioenergetic needs. Androgens play a key role in the metabolism of PCa that
influences several lipogenic and lipolytic enzymes. PCa metabolism in the
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absence of androgen is less studied and here we observed that PCa cells ramp
up an alternate pathway of lipolysis in the absence of androgens, which could
provide a survival strategy during hormone ablation therapy.
Autophagy has long been known to contribute significantly to cellular
energetic balance, especially during periods of starvation, but its role in
mediating lipolysis has only recently been established. Singh and colleagues
reported that autophagosomes sequestered lipid droplets and target them to
lysosomes for lipolysis in rat hepatocytes (83). The increased delivery of lipid
droplets was observed under conditions of starvation or lipid overload.
Autophagy-mediated lipolysis was also reported in adipocytes and other cell
types, but not in PCa cells.
Lysosomes are vesicles that contain acidic lipases. Lipid droplets targeted
to lysosomes through the autophagic machinery cause bulk lipolysis and cleave
triglycerides into fatty acids. The released fatty acids can provide precursors for
energy during androgen deprivation.

4.3. Effect of Chloroquine, an autophagy inhibitor, in survival
and bioenergetic status of LNCaP cells.
With our increased understanding of the effects of autophagy in survival of
cancer cells, modulation of autophagy as an adjunct to enhance the killing effect
of existing therapeutic agents has become a topic of intense interest. We and
others have shown that autophagy plays a protective role during androgen
deprivation in PCa cells. We further identified that autophagy mediates lipolysis
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by targeting lipid droplets to lysosomes for hydrolysis. Recently, chloroquine
(CLQ) and other members of this family of drugs have been used to block
autophagy by preventing autophagolysosomal degradation (135). Thus, we used
CLQ for combination treatment with hormone ablation therapy in LNCaP cells
and characterized the effects on cell death and bioenergetic status.
In this study, we observed that CLQ synergistically killed LNCaP cells
during androgen deprivation in a dose- and time-dependent fashion. The higher
the concentration, the better was the killing effect. Interestingly, treatment with
CLQ for longer durations also significantly enhanced the killing effect. This is
particularly important in the context that CLQ has long half life in the body (2–6
days). At 200 μM, a reduction of more than 50% reduction in cell number was
observed on day 3 of androgen deprivation whereas there was no effect of CLQ
in cells growing in the presence of androgen.
Confocal microscopy of CLQ treated EGFP-LC3 expressing LNCaP
cells, revealed increased accumulation of puncta, which were presumably the
autophagic vacuoles. Furthermore, CLQ treatment reduced the intracellular ATP
level, supporting the role of autophagy in supplying energy precursors during
androgen deprivation.
To characterize the cell death pathway activated during CLQ treatment,
cells were labeled with Annexin V-FITC and propidium iodide and analyzed by
flow cytometry. This showed that an increased percentage of cells died through
apoptosis in the group co-treated with CLQ and androgen deprivation. Enhanced
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apoptosis in the co-treated group was further confirmed by using a DNA ladder
assay and direct observation of crescent shaped and fragmented nuclei.
CLQ has been used as a drug in clinical practice for more than 60 years
and is currently widely used for prophylaxis and treatment in malaria, rheumatoid
arthritis, and lupus (135-137). Recently, its application as an adjunct in cancer
therapy has emerged because of its known function in cellular physiology. CLQ is
a weak base and has a wide distribution in the human body. It has a tendency to
accumulate in acidic vesicles such as lysosomes and neutralize the pH, which
inactivates lysosomal enzymes (138, 140). This effect of CLQ is potentially
important in cancer therapies where cells induce autophagy as a protective
mechanism. Recently, it was observed that 5-FU induces autophagy in HT-29
colon cancer cells, and co-treatment with CLQ inhibits autophagosomal
degradation and potentiates the anti-cancer effect of 5-FU (146). In another
study, CLQ induced accumulation of autophagic vacuoles in 5 different
glioblastoma cell lines and affected the survival of these cells (147). These
findings suggest that altered lysosomal function may play a role in CLQ induced
cell death. Inhibition of autophagy by CLQ also sensitizes PCa cells to Src family
kinase inhibitors like saracatinib and PP2 in both LNCaP and PC3 cells (149).
Moreover, combination treatments of CLQ or its analogs with many established
chemotherapeutic agents are already in different phases of clinical trials. Notably,
co-treatment with hydroxychloroquine and docetaxel in PCa showed a synergistic
killing effect on PCa cells and is already in phase II clinical trials (135).
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The effect of CLQ on autophagic degradation was similar to the effect seen
with Bafilomycin A1 treatment which also increases the pH of lysosome by
inhibiting the H+ K+ ATPase. In chapter 2, we showed that Bafilomycin A1
treatment of LNCaP cells caused the accumulation of autophagic vesicles and
inhibited lipophagy.

4.4 Limitations and future implications
The experimental findings presented in this work imply several limitations
that need to be addressed further. In this section these limitations will be
explained as they pertain to each of the important findings and possible future
implications will be highlighted.
4.4.1 Autophagy during androgen deprivation
Literature reviews show that the first evidence of autophagy inhibition by
androgens date back to 1999 when Kwong et al. reported increased autophagic
vesicles in the prostate of castrated mice (50). This observation was from the
normal prostate gland. Later, Xu et al. showed that androgens activate the
mTOR pathway and promote proliferation of LNCaP cells (48). As the mTOR
pathway is a key regulator of autophagy, it was speculated that autophagy may
be induced during androgen deprivation. In 2008, Li et al. showed that incubation
of LNCaP cells in a serum-free medium induces autophagy, which is abrogated
on addition of an androgen analog (49). This study further showed that androgen
deprivation was also associated with low mTOR activity as evidenced by loss of
phosphorylation of p70S6K (Thr421/Ser424). Consistent with these reports,
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another group recently showed that incubation of LNCaP cells in a serum-free
medium under hypoxic conditions activates the AMPK pathway and increases
autophagy (172).
As most animal serum samples used in tissue culture medium contain
several growth factors including androgens, we tried to mimic androgendeprivation conditions by using medium containing charcoal-filtered serum.
Charcoal filters out most of the androgens along with other steroid factors. Thus,
a charcoal-filtered serum medium mimics the hormone ablation therapy better
than the serum free medium, but still these conditions may vary from what occurs
in human tissues in vivo. We further confirmed the inhibition of autophagy by
androgens in another androgen sensitive PCa cell line, LAPC4. However, all
these are in vitro experiments. Thus, further evaluation of autophagic activity are
required either using PCa tissue samples from patients who have undergone
hormone ablation therapy, or tissue samples from experimental animal models of
hormone sensitive PCa cells.
Although autophagy inhibition significantly enhanced the killing of
androgen-deprived PCa cells, it cannot be guaranteed that it will alter the course
of PCa progression in patients. When LNCaP cells were continuously cultured in
androgen-deprived medium, almost all cells were dead by the end of the third
week (our observations). In human PCa patients, hormone ablation therapy
causes regression of tumors. However, after an indefinite period (mostly in
years), most patients show remission of PCa with an androgen/castrationindependent phenotype. Studies have identified multiple mechanisms of how
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PCa cells can survive in the absence of androgens, but the molecular
mechanisms of progression to that stage are still elusive. One possibility is that
during hormone ablation therapy, some of these cancer cells go into a dormant
phase and later recommence proliferation when the environment becomes
favorable. In this study, we did not directly address the effect of autophagy on
progression to the androgen-independent phenotype. However, it is possible that
killing the hormone sensitive PCa cells in a more effective way may lower the
chance of evasion of cell death and progression to an androgen-independent
phenotype.
4.4.2 Function of autophagy in lipid metabolism in hormone sensitive
Prostate cancer cells
Regulation of lipolysis by autophagy, also named lipophagy, is a novel
function of autophagy that was first reported in 2009 (83). Soon after, a number
of cancer cell types were also reported to use the autophagic machinery for
regulating lipid metabolism (84-90). In chapter 2, we characterized this novel
function of autophagy in hormone-sensitive PCa cells.
As previously discussed, it is possible that our observations in cellular
systems may not accurately represent cell responses in vivo. Lipophagy during
androgen deprivation at least should be tested in autophagy-deficient prostate
glands in an animal model. In addition, further studies are needed to elucidate
the mechanism of lipid droplet sequestration by autophagosomes. Is it a selective
process? Are there specific adaptor proteins used to target the lipid droplets to
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autophagosomes? We do not have the answers, yet several lines of evidence
suggest that autophagosomes may start to form on lipid droplets. Because
nutrient starvation also induced lipophagy in our cell systems, it is possible that
lipophagy is a common cellular stress response to altered metabolic status.
4.4.3 Chloroquine as an adjuvant in hormone ablation therapy.
In chapter 3, I showed that CLQ synergistically killed androgen-deprived
LNCaP cells through apoptosis. There are several limitations in those
experiments that need to be addressed before CLQ can be repurposed as an
adjuvant in hormone-sensitive PCa.
In our experiments, we used 200 μM of CLQ to treat the cells. Alhough,
only 15% cell death was observed after 24 hours, it was more pronounced on
day 2 and day 3. As CLQ has a long half life in vivo, we treated the cells with
CLQ for 36 hours to 48 hours to characterize the pathways activated during the
treatment. There is limited research on the bioavailability of CLQ in prostate
gland. Because response to CLQ is dose dependent, bioavailability in PCa cells
in vivo is an important factor. Thus, in the future a key study will be to test the
efficacy of the co-treatment of CLQ and androgen deprivation in animal models
of PCa.
There are other available analogs of the CLQ family, such as
hydroxychloroquine, mefloquine, quinine, quinacrine, NSC305819, NSC10010
and NSC86371. These compounds may have variable therapeutic efficacy in
different cancer cell systems, and therefore they should be tested and then
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compared with CLQ to identify the best adjuvant to synergize with hormone
ablation therapy.
As discussed earlier, co-treatment of CLQ and androgen deprivation
should be tested for its impact on progression to an androgen-independent
phenotype, both in vivo and in vitro. Previously, LNCaP cells have been cultured
continuously in androgen-deprived medium for several passages, and shown the
formation of clones that were androgen independent. One can test how CLQ
affects the generation of androgen independent clones in vitro, but the real
impact in vivo can only be assessed in longitudinal clinical studies.

4.5 Summary
The present work probed the function of autophagy on lipid metabolism
and survival in hormone sensitive PCa cells. Two different androgen sensitive
PCa cells underwent autophagy during androgen deprivation, which is one of the
standard treatments for early-stage hormone sensitive PCa. The
autophagosomes generated in response to androgen removal mediated an
alternative lipolytic pathway. Pharmacologic inhibition of autophagy caused
retention of lipid droplets and triglycerides. Similar results were observed after
genetic siRNA-based inhibition of autophagy. Furthermore, autophagosomes
were observed to colocalize with lipid droplets during androgen deprivation.
These findings demonstrate that, in the absence of androgens, autophagy was
activated in hormone sensitive PCa cells with the consequence that lipid droplets
were sequestered and targeted to the lysosomes for hydrolysis. Consistent with
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this model, inhibition of autophagolysosomal degradation caused retention of
intracellular triglycerides.
Autophagy induced during androgen ablation aided in survival of these
cancer cells. Inhibition of autophagy caused a synergistic cell death effect during
androgen deprivation in a dose- and time-dependent manner. It also caused a
decrease in intracellular ATP levels. Moreover, cells died through apoptosis
when autophagy was inhibited during androgen deprivation.
PCa cells are rich in lipid droplets and rely on lipid metabolism for their
bioenergetic needs. The identification of lipophagy in PCa cells shows how
cancer cells ramp up alternate metabolic pathways for their survival.
Characterization of the effects on cell death of the autophagy inhibitor CLQ
during androgen deprivation opens the possibility of repurposing CLQ as an
adjunct in hormone ablation therapy in PCa.

93

List of abbreviations
3-MA

3-methyladenine

ACAT

Acetyl-Coenzyme A acetyltransferase

ADRP

Adipose Differentiation Related Protein

AMPK

Adenosine Monophosphate-Activated Protein Kinase

AR

Androgen receptor

ARE

Androgen response element

ATGL

Adipose Triglyceride Lipase

AVs

Autophagic vacuoles

Baf A1

Bafilomycin A1

CDX

Casodex (Bicalutamide)

CFM

Charcoal filtered serum containing medium

CLQ

Chloroquine

CM

Complete medium

CMA

Chaperone mediated autophagy

DAP1

Death associated protein 1

DGAT

Diglyceride acyltransferase

DHT

Dihydrotesteterone

FAS

Fatty acid synthase

FBS

Fetal bovine serum

FIP 200

Focal adhesion kinase [FAK] family interacting protein

HSL

Hormone sensitive lipase

MAP-LC3

Microtubule associated protein - light chain 3
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mTOR

Mammalian target of Rapamycin

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NCI

National cancer institute

NMR

Nuclear magnetic resonance

PBS

Phosphate buffer solution

P53

Tumor protein 53

P70S6K

p70 ribosomal protein S6 kinase

PCa

Prostate cancer

PI3K

Phosphoinositide 3-kinase

PKA

Protein kinase A

ROS

Reactive oxygen species

SREBP

Sterol Regulatory Element-Binding Proteins

TG

Triglycerides

TIP47

Tail-interacting protein of 47 kDa

TNF-α

Tumor necrosis factor-α

TSC2

Tuberous sclerosis protein 2

Vps34

Vacuolar protein sorting protein 34
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